Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PTPRC | P08575 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5664578 | 0.88 | EPHX2 (0.46) | MLYCDHPGDNPSR1PTPRCKDM4E | |
| SCHEMBL4495372 | 0.88 | EPHX2 (0.48) | MLYCDHPGDNPSR1PTPRCCYP1A2 | |
| SCHEMBL5663110 | 0.85 | TP53BP1 (0.51) | PTPRCKMT2A | |
| SCHEMBL9430861 | 0.84 | EPHX2 (0.39) | MLYCDHPGDNPSR1PTPRCCYP1A2 | |
| SCHEMBL27624024 | 0.84 | FOLH1 (0.39) | MLYCDHPGDNPSR1PTPRCFOLH1 | |
| SCHEMBL4503693 | 0.82 | MEN1 (0.53) | KDM4EALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL6829407 | 0.81 | NR1H4 (0.54) | NPSR1ALDH1A1 | |
| SCHEMBL6289410 | 0.80 | EPHX2 (0.42) | PTPRCALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL27474422 | 0.80 | EPHX2 (0.42) | PTPRCALDH1A1MEN1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL6829405 | 0.80 | NR1H4 (0.53) | NPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1435932-A4 | INHIBITORS OF RNASE P PROTEINS AS ANTIBACTERIAL COMPOUNDS | MESSAGE PHARMACEUTICALS INC (US) | 2006-12-06 | — | — | EP | disclosed |
| US-7001924-B2 | Inhibitors of RNase P proteins as antibacterial compounds | MESSAGE PHARMACEUTICALS (US) | 2006-02-21 | — | — | US | disclosed |
| EP-1435932-A2 | INHIBITORS OF RNASE P PROTEINS AS ANTIBACTERIAL COMPOUNDS | Message Pharmaceuticals, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20030134904-A1 | Inhibitors of RNase P proteins as antibacterial compounds | S.R. ONE, LIMITED | 2003-07-17 | — | — | US | disclosed |
| WO-2003024407-A2 | INHIBITORS OF RNASE P PROTEINS AS ANTIBACTERIAL COMPOUNDS | MESSAGE PHARMACEUTICALS, INC. (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134904-A1 | Inhibitors of RNase P proteins as antibacterial compounds | RNASEH1, RNASEL, SNRPA | MLYCD 2861/4885HPGD 4076/4885NPSR1 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.